Advances in the Treatment of NTRK Fusion-positive Cancers

This series explores new developments in the molecular pathology and management of NTRK fusion-positive cancers.

EP. 1: Targeting the TRK Pathway in Pediatric or Adult Patients with Advanced or Surgically Unresectable NTRK Fusion-positive Solid Tumors

December 23rd 2021

FDA-approved TRK inhibitors entrectinib and larotrectinib have demonstrated safety and efficacy in treating a variety of solid tumors.

EP. 2A: The Effect of Larotrectinib on the Treatment Landscape for NTRK Fusion-positive Cancers

January 27th 2022

In this first video of the series, Steven G. Waguespack, MD, of the University of Texas MD Anderson Cancer Center provides an overview of the safety and efficacy of larotrectinib and considers how it has impacted the treatment landscape for NTRK fusion-positive cancers.

EP. 2B: The Impact of Updated Sub-Analysis Data on the Role of Larotrectinib for NTRK Fusion-positive Thyroid Cancer

February 14th 2022

In the first interview of this series, Steven G. Waguespack, MD, considers long-term safety and efficacy data on larotrectinib and discusses implications for the treatment landscape for NTRK fusion-positive thyroid cancer.

EP. 3A: Treatment Considerations for Patients With TRK Fusion-positive Cancers

March 31st 2022

In the second video of the series, Marcia Brose, MD, PhD, from the Sidney Kimmel Cancer Center – Jefferson Health shares key insights into factors affecting treatment decisions for patients with TRK fusion-positive cancers including the consideration of comorbidities and adverse event profiles.

EP. 3B: Factors Affecting Therapeutic Selection for NTRK Fusion-positive Thyroid Cancer

April 26th 2022

In the second interview of the series, Marcia Brose, MD, PhD, reviews currently available therapies for NTRK fusion-positive thyroid cancer and highlights clinical factors affecting treatment decision-making.

EP. 4A: First -generation TRK Inhibitors and Treatment Resistance in NTRK Fusion-positive Cancers

April 27th 2022

In the third video interview of the series, David S. Hong, MD, from the University of Texas MD Anderson Cancer Center discusses the safety and efficacy of first-generation TRK inhibitors and reflects on challenges affecting next-generation TRK inhibitors including research into mechanisms of treatment resistance.

EP. 4B: Understanding Treatment Resistance in First-Generation TRK Inhibitors for the Treatment of NTRK Fusion-Positive Cancers

May 13th 2022

In this companion article, David S. Hong, MD, considers the safety and efficacy of the first-generation TRK inhibitor larotrectinib and discusses how acquired resistance may affect research into second-generation agents.